XML 39 R24.htm IDEA: XBRL DOCUMENT v3.24.2
Other Operating Income And Expenses
 6 Months Ended
Jun. 30, 2024
Analysis of income and expense [abstract]  
Other Operating Income and Expenses
B.15. OTHER OPERATING INCOME AND EXPENSES
Other operating income amounted to €617 million in the first half of 2024 (versus €617 million in the first half of 2023), and Other operating expenses to €2,010 million (versus € 1,422 million in the first half of 2023).
The main items included in Other operating income were: in the first half of 2024, (i) income from pharmaceutical partners of €118 million (versus €160 million in the first half of 2023), of which €96 million came from Regeneron (versus €102 million in the first half of 2023, see table below) and (ii) gains on disposals of assets and operations of €389 million, primarily on divestments of non strategic products (versus €413 million in the first half of 2023).
Other operating expenses for the first half of 2024 included €1,841 million of expenses related to Regeneron (compared with €1,423 million in the first half of 2023), as shown in the table below.
(€ million)June 30, 2024 (6 months)June 30, 2023 (6 months)
December 31, 2023
(12 months)
Income & expense related to profit/loss sharing under the Monoclonal Antibody Alliance(1,934)(1,449)(3,321)
Additional share of profit paid by Regeneron towards development costs389 291 668 
Reimbursement to Regeneron of selling expenses incurred(292)(260)(543)
Total: Monoclonal Antibody Alliance(1,837)(1,418)(3,196)
Other (mainly Zaltrap and Libtayo)
92 97 217 
Other operating income/(expenses), net related to Regeneron (1,745)(1,321)(2,979)
of which amount presented in “Other operating income” 96 102 227